Tirzepatide Superior to Intensified Conventional Care for Early Type 2 Diabetes

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 27, 2026.

via HealthDay

WEDNESDAY, May 27, 2026 -- Tirzepatide is superior to intensified conventional care (ICC) for adults with early type 2 diabetes (T2D) uncontrolled with metformin, according to a study published online May 26 in the Annals of Internal Medicine.

Stefano Del Prato, M.D., from the Sant'Anna School of Advanced Studies in Pisa, Italy, and colleagues examined the efficacy and safety of tirzepatide versus ICC in participants with early T2D who have inadequate glycemic control with diet, exercise, and metformin in a randomized phase 4 trial involving 794 adults with a maximum of four years of T2D history. Participants were randomly assigned to receive tirzepatide (15 mg or maximum tolerated dose) or ICC (including glucagon-like peptide-1 receptor agonists but excluding tirzepatide).

The researchers found that for mean changes from baseline to two years, tirzepatide was superior to ICC for hemoglobin A1c (−1.99 versus −1.32 percentage points; estimated treatment difference [ETD], −0.68 percentage points), weight (ETD, −8.0 kg), and waist circumference (ETD, −6.2 cm). Normoglycemia (hemoglobin A1c <5.7 percent) was achieved by more participants receiving tirzepatide than ICC (60.2 versus 24.0 percent). In both groups, gastrointestinal adverse events were the most common.

"These findings support the concept that early initiation of tirzepatide treatment could establish better and potentially more durable glycemic control than can be achieved with conventional care," the authors write.

The study was funded by Eli Lilly, the manufacturer of tirzepatide.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-28 03:09

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords